GMED:NYE-Globus Medical Inc. Class A (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 65.61

Change

0.00 (0.00)%

Market Cap

USD 2.00B

Volume

0.59M

Analyst Target

USD 60.85
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Globus Medical Inc is a medical device company focused on developing products that promote healing in patients with musculoskeletal disorders. The Company also develops a robotic surgical navigation device and products to treat patients.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-16 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

+0.12 (+0.11%)

USD 196.14B
MDT Medtronic PLC

+0.06 (+0.07%)

USD 115.25B
STE STERIS plc

+0.34 (+0.14%)

USD 23.37B
ZBH Zimmer Biomet Holdings Inc

+1.21 (+1.14%)

USD 21.67B
SNN Smith & Nephew SNATS Inc

+0.29 (+0.95%)

USD 13.37B
BIO Bio-Rad Laboratories Inc

+16.55 (+5.24%)

USD 9.32B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 8.85B
PEN Penumbra Inc

+4.74 (+2.54%)

USD 7.80B
GKOS Glaukos Corp

+1.19 (+0.94%)

USD 7.15B
INSP Inspire Medical Systems Inc

-1.32 (-0.63%)

USD 6.35B

ETFs Containing GMED

CYBG:LSE VanEck Bionic Engineering.. 3.35 % 0.00 %

-0.13 (-0.84%)

N/A
EASI 2.82 % 0.75 %

N/A

N/A
GGEM:CA 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.12% 82% B 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.12% 82% B 92% A
Trailing 12 Months  
Capital Gain 11.91% 71% C- 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.91% 71% C- 62% D
Trailing 5 Years  
Capital Gain 56.40% 85% B 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.40% 80% B- 70% C-
Average Annual (5 Year Horizon)  
Capital Gain 5.23% 42% F 59% D-
Dividend Return 5.23% 42% F 52% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 26.19% 73% C 41% F
Risk Adjusted Return 19.96% 45% F 43% F
Market Capitalization 2.00B 73% C 83% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 17.60 17% 5%
Price/Book Ratio 1.75 72% 47%
Price / Cash Flow Ratio 36.39 21% 6%
Price/Free Cash Flow Ratio 20.19 24% 14%
Management Effectiveness  
Return on Equity 2.28% 63% 33%
Return on Invested Capital 2.89% 52% 34%
Return on Assets 5.27% 88% 74%
Debt to Equity Ratio 10.44% 90% 87%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.